- Therapies for Children with Autism Spectrum Disorders [Entered Retrospectively]
- The Vanderbilt Evidence-based Practice Center systematically reviewed evidence on therapies for children ages 2 to 12 with autism spectrum disorders (ASDs). We focused on treatment outcomes, modifiers of treatment effectiveness, evidence for generalization of outcomes to other contexts, and evidence to support treatment decisions in children ages 0-2 at risk for an ASD diagnosis.
- Authors of Report
- Methodology description
- We included studies published in English from January 2000 to May 2010. We excluded medical studies with fewer than 30 participants; behavioral, educational, and allied health studies with fewer than 10 participants; and studies lacking relevance to treatment for ASDs.
- *** The systematic review data of this published project was retrospectively imported into SRDR by the Brown EPC on behalf of the Vanderbilt Evidence-based Practice Center and the Agency for Healthcare Research and Quality (AHRQ). For access to the full report available on the AHRQ website, follow this link: http://effectivehealthcare.ahrq.gov/search-for-guides-reviews-and-reports/?pageaction=displayproduct&productID=656 ***
This systematic review of the literature will address the following key questions:
KQ 1: Among children ages 2-12 with ASDs, what are the short- and long-term effects of available behavioral, educational, family, medical, allied health, or CAM treatment approaches? Specifically,
KQ 1a: What are the effects on core symptoms (e.g., social deficits, communication deficits, and repetitive behaviors) in the short term (< = 6 months)?
KQ 1b: What are the effects on commonly associated symptoms (e.g., motor, sensory, medical, mood/anxiety, irritability, and hyperactivity) in the short term (< = 6 months)?
KQ 1c: What are the longer term effects (>6 months) on core symptoms (e.g., social deficits, communication deficits, and repetitive behaviors)?
KQ 1d: What are the longer term effects (>6 months) on commonly associated symptoms (e.g., motor, sensory, medical, mood/anxiety, irritability, and hyperactivity)?
KQ 2: Among children ages 2-12, what are the modifiers of outcome for different treatments or approaches?
KQ 2a: Is the effectiveness of the therapies reviewed affected by the frequency, duration, and intensity of the intervention?
KQ 2b: Is the effectiveness of the therapies reviewed affected by the training and/or experience of the individual providing the therapy?
KQ 2c: What characteristics, if any, of the child modify the effectiveness of the therapies reviewed?
KQ 2d: What characteristics, if any, of the family modify the effectiveness of the therapies reviewed?
KQ 3: Are there any identifiable changes early in the treatment phase that predict treatment outcomes?
KQ 4: What is the evidence that effects measured at the end of the treatment phase predict long- term functional outcomes?
KQ 5: What is the evidence that specific intervention effects measured in the treatment context generalize to other contexts (e.g., people, places, materials)?
KQ 6: What evidence supports specific components of treatment as driving outcomes, either within a single treatment or across treatments?
KQ 7: What evidence supports the use of a specific treatment approach in children under the age of 2 who are at high risk of developing autism based upon behavioral, medical, or genetic risk factors?
| Abbreviations for Appendix G - Table 1:
AAC- augmentative and alternative communication; ASD-autism spectrum disorders; EIBI-early intensive behavioral intervention; PECS-Picture Exchange Communication System; RPMT- Responsive Education and Prelinguistic Milieu Teaching; td-treatment |
- Funding Source
- The Agency for Healthcare Research and Quality (AHRQ)